Previous 10 | Next 10 |
2023-10-20 17:11:41 ET More on Cardiol Therapeutics Seeking Alpha’s Quant Rating on Cardiol Therapeutics Historical earnings data for Cardiol Therapeutics Financial information for Cardiol Therapeutics For further details see: Cardiol Therapeutics ...
--News Direct-- Toronto, ON, October 13, 2013 ( PlatoData via 500NewsWire) -- In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances cont...
--News Direct-- Cardiol Therapeutics CEO David Elsley joined Steve Darling from Proactive with news the company has unveiled highly promising study results from international research, which showcased the remarkable potential of subcutaneously administered cannabidiol, the active pharmace...
Results Demonstrate the Active Pharmaceutical Ingredient in Cardiol's Novel CRD-38 Formulation Attenuates Harmful Fat Distribution and Key Markers of Cardiac Inflammation and Remodelling Data Presented at the Heart Failure Society of America Annual Scientific Meeting 2023 Toronto, Ontario--...
Toronto, Ontario--(Newsfile Corp. - September 26, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treat...
Recruitment Accelerating and Full Patient Enrollment Anticipated to be Completed During Q3 2024, up to Six Months Ahead of Schedule Multi-Center, International, Double-blind, Placebo-controlled Trial Randomizing 100 Patients Toronto, Ontario--(Newsfile Corp. - September 19, 2023) - Car...
Toronto, Ontario--(Newsfile Corp. - August 9, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment...
2023-08-08 08:33:20 ET Cardiol Therapeutics ( NASDAQ: CRDL ) received notice from Nasdaq stating the company has regained compliance with the minimum bid price requirement. The company is now in compliance with all applicable listing standards. For further details se...
Oakville, Ontario--(Newsfile Corp. - August 8, 2023) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
Oakville, Ontario--(Newsfile Corp. - June 29, 2023) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatme...
News, Short Squeeze, Breakout and More Instantly...
Cardiol Therapeutics Inc. Company Name:
CRDL Stock Symbol:
NASDAQ Market:
Cardiol Therapeutics Inc. Website:
Toronto, Ontario--(Newsfile Corp. - June 27, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...
2024-06-26 06:30:06 ET B. Riley analyst issues BUY recommendation for CRDL on June 26, 2024 04:52AM ET. CRDL was trading at $2.12 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy recommendations . ...
Toronto, Ontario--(Newsfile Corp. - June 25, 2024) - Cardiol Therapeutics Inc. ( NASDAQ: CRDL ) ( TSX: CRDL ) (" Cardiol " or the " Company "), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatmen...